Making Healthcare Smarter: Quest Diagnostics

September 2nd, 2016
Posted by


Industry leader Quest Diagnostics recently announced the release of CogniSense, its digital cognitive testing technology. This important new tool is designed to help physicians and accountable care organizations (ACO) improve the detection and monitoring of patients with dementia and Alzheimer’s disease, as well as other types of cognitive dysfunction.

CogniSense’s design solves the limitations associated with conventional, paper-based assessments. The app represents a type of clinical testing that Quest calls “integrated diagnostics,” which will streamline the process of tracking and storing patient data.

Integrated Diagnostics

“Integrated diagnostics will be increasingly important to neurological disease diagnosis, particularly dementia, given the dearth of evidence-based guidelines and reliable technologies for facilitating assessment and diagnosis for the globally aging population,” says Jay G. Wohlgemuth, MD, senior vice president and chief medical officer at Quest.

The iPad app is currently available on iTunes. It “addresses a gap in cognitive health assessment today,” says Edward I. Ginns, MD, PhD, medical director, neurology, for Quest Diagnostics. “[There is] a lack of digital technology that seamlessly integrates results into a patient’s electronic health records to track cognitive function and disease progression over time.”

Quest’s new “integrated diagnostics” approach represents an example of the clinical and technology trends that drive Smarter Healthcare. Specifically, CogniSense is affordable and easy to administer. In addition, by providing an objective understanding of a patient’s cognitive impairment, it can improve patient medication and treatment compliance, as well as reduce costly hospital remittance.

Smarter Healthcare

Found at the intersection of technology, clinical practice, and market shifts, Smarter Healthcare is a comprehensive way of thinking about the dynamic forces that exist in our industry today. Companies like Quest Diagnostics that understand and address each of these elements are best positioned to respond to the needs of our changing healthcare landscape.

Quest Diagnostics is championing the development of new integrated diagnostics that combine multiple diagnostic modalities such as cognitive assessment, laboratory testing, imaging, and clinical knowledge to aid in the detection and diagnosis of dementia. Through a collaboration with the University of California, San Francisco (UCSF) Memory and Aging Center, Quest Diagnostics is also facilitating the development of evidence-based standards for screening, diagnosis, and monitoring of people with dementia to help improve outcomes and better address the needs of the nation’s aging population.

In pursuing this path, Quest Diagnostics is a shining example of a company that is expanding beyond its traditional niche of analyzing physiological biomarkers and complementing its diagnostic offerings with information technology. The result – CogniSense – is a solution that addresses the convergence of technology, clinical practice, and market shifts. As Quest moves to become the world’s leading provider of diagnostic information services, it is making healthcare smarter by empowering people to take action to improve health outcomes.


At Popper and Company, we look for every opportunity to create value through Smarter Healthcare. In our dynamic model, we approach every challenge by thinking unconventionally about these components to create new opportunities for growth, routes to market, and product offerings for our clients.

Visit our What We Do page to learn more about our approach or give us a call at(410) 246-6524.

Like this content? Don’t miss an update.

About the Author:

I am a business leader with over 25 years of experience in managing companies providing consulting, clinical research, informatics/digital, and commercialization services to the life sciences industries. My specific area of expertise is in helping novel medical technologies with scientific and clinical promise make the transition to becoming successful commercial enterprises. Send me an email.